Literature DB >> 2112466

Susceptibility of mycobacteria to fusidic acid.

S E Hoffner1, B Olsson-Liljequist, K J Rydgård, S B Svenson, G Källenius.   

Abstract

Fusidic acid was shown to be effective in vitro against 30 clinical isolates of Mycobacterium tuberculosis at concentrations of 32-64 mg/l, concentrations which are readily achieved in serum. All but one of 17 Mycobacterium avium complex strains were resistant to fusidic acid at concentrations up to 64 mg/l. However, synergistic effects were shown for 11 of the 17 strains when fusidic acid was combined with ethambutol. Five of the strains were fully susceptible to the combination of fusidic acid (64 mg/l) and ethambutol (4 mg/l). It is suggested that fusidic acid should be evaluated clinically as a potential supplementary drug for treatment of mycobacterial infections.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2112466     DOI: 10.1007/bf01968066

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  13 in total

1.  Fucidin: a new orally active antibiotic.

Authors:  W GODTFREDSEN; K ROHOLT; L TYBRING
Journal:  Lancet       Date:  1962-05-05       Impact factor: 79.321

2.  Synergistic effects of antimycobacterial drug combinations on Mycobacterium avium complex determined radiometrically in liquid medium.

Authors:  S E Hoffner; S B Svenson; G Källenius
Journal:  Eur J Clin Microbiol       Date:  1987-10       Impact factor: 3.267

Review 3.  The pharmacokinetics of fusidic acid.

Authors:  D S Reeves
Journal:  J Antimicrob Chemother       Date:  1987-10       Impact factor: 5.790

4.  Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis.

Authors:  S H Siddiqi; J P Libonati; G Middlebrook
Journal:  J Clin Microbiol       Date:  1981-05       Impact factor: 5.948

5.  The disposition of sodium fusidate in man.

Authors:  R Wise; M Pippard; M Mitchard
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

6.  Studies on the mechanisms of the synergistic effects of ethambutol and other antibacterial drugs on Mycobacterium avium complex.

Authors:  S E Hoffner; G Källenius; A E Beezer; S B Svenson
Journal:  Acta Leprol       Date:  1989

7.  Automatable radiometric detection of growth of Mycobacterium tuberculosis in selective media.

Authors:  G Middlebrook; Z Reggiardo; W D Tigertt
Journal:  Am Rev Respir Dis       Date:  1977-06

8.  Infections caused by Mycobacterium avium complex in immunocompromised patients: diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristics.

Authors:  T E Kiehn; F F Edwards; P Brannon; A Y Tsang; M Maio; J W Gold; E Whimbey; B Wong; J K McClatchy; D Armstrong
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

9.  Improved detection of Mycobacterium avium complex with the Bactec radiometric system.

Authors:  S E Hoffner
Journal:  Diagn Microbiol Infect Dis       Date:  1988-05       Impact factor: 2.803

10.  Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects.

Authors:  L B Heifets; M D Iseman; P J Lindholm-Levy
Journal:  Am Rev Respir Dis       Date:  1988-03
View more
  3 in total

1.  Fusidic acid is highly active against extracellular and intracellular Mycobacterium leprae.

Authors:  S G Franzblau; A N Biswas; E B Harris
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

2.  Susceptibility of Mycobacterium kansasii to ofloxacin, sparfloxacin, clarithromycin, azithromycin, and fusidic acid.

Authors:  R S Witzig; S G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

3.  Clinical trial of fusidic acid for lepromatous leprosy.

Authors:  S G Franzblau; G P Chan; B G Garcia-Ignacio; V E Chavez; J B Livelo; C L Jimenez; M L Parrilla; R F Calvo; D L Williams; T P Gillis
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.